Capabilities · Manufacturing
Sterile manufacturing, built for oncology injectables
Naprod's single manufacturing site sits in MIDC Tarapur, Boisar, Maharashtra — one plant, one quality system, running sterile lyophilized and liquid injectables alongside oral solid dose, under EU-GMP and WHO-GMP process controls.
163 products in active production (100 FDF, 63 API) · plant DUNS 915076185 · manufacturing since 1994
The site
MIDC Tarapur, Boisar
A single, centrally managed manufacturing site in the MIDC Tarapur industrial estate, Boisar, Maharashtra — registered under DUNS 915076185. Consolidating sterile injectable and oral solid dose production on one site keeps the quality system, environmental monitoring program, and regulatory inspection history under one roof, rather than split across contract sites.
Dosage forms
Four production lines, one site
The plant runs four dosage-form lines: lyophilized (freeze-dried) sterile injectables, liquid sterile injectables, tablets, and capsules — plus active pharmaceutical ingredient (API) synthesis supplied through group company MacChem. Oncology, anesthesia, and critical-care injectables account for the largest share of sterile output; the tablet and capsule lines carry general and supportive-care formulations.
Quality control
Process controls behind the line
Manufacturing at Tarapur runs under process controls aligned to EU-GMP and WHO-GMP. The plant's GMP certification with ANVISA (Brazil) was renewed in January 2026, reported by Pharma India Magazine. A full register of accreditations — detailed and being-digitized — is maintained on the Quality page, including EU-GMP, INVIMA (Colombia), UAE Ministry of Health, NHRA Bahrain, and WHO-GMP.
Capacity
Installed annual capacity
Six capacity figures below are carried over from company draft materials and the previous naprodgroup.com site. They have not yet been reconfirmed against current production records and are shown with a pending-confirmation label until the company verifies them.
| Line | Installed capacity |
|---|---|
| Oncology lyophilized injectables | 3.5M units/yr |
| Oncology liquid injectables | 3M units/yr |
| Tablets | 30M units/yr |
| Capsules | 15M units/yr |
| General lyophilized injectables | 10M units/yr |
| General liquid injectables | 1M units/yr |
Pending approval Figures pending confirmation — carried over from company draft/old-site copy, not yet reconfirmed for current output.
Facility
Facility schematic
A block schematic of the Tarapur site — sterile core, lyophilization suite, oral solid dose block, warehousing, and utilities — is placeholder pending an as-built layout release from the site engineering team.
Pending approval Facility schematic is a placeholder diagram — awaiting as-built layout release from site engineering.
Photography
Shot list — awaiting site visit
Photography across this page is a dashed placeholder frame pending a scheduled site visit. Planned shots: (1) plant exterior / site signage, (2) sterile core corridor (gowned, through-viewport), (3) lyophilizer bank, (4) tablet compression line, (5) capsule filling line, (6) QC/analytical lab bench, (7) warehousing and cold-chain dispatch bay.
-
Shot 1 — Plant exterior and site signage, MIDC Tarapur -
Shot 2 — Sterile core corridor (gowned personnel, through-viewport only) -
Shot 3 — Lyophilizer bank -
Shot 4 — Tablet compression line -
Shot 5 — Capsule filling line -
Shot 6 — QC / analytical laboratory bench -
Shot 7 — Warehousing and cold-chain dispatch bay
Pending approval All photography on this page is a placeholder — awaiting scheduled site photography.